199 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
33
Rationally designed"dipeptoid" analogues of CCK. A Free-Wilson/Fujita-Ban analysis of some alpha-methyltryptophan derivatives as CCK-B antagonists.
Parke-Davis Neuroscience Research Centre
49
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
Jagiellonian University Medical College
47
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
Jagiellonian University Medical College
2
Molecular Mechanism of Action of Triazolobenzodiazepinone Agonists of the Type 1 Cholecystokinin Receptor. Possible Cooperativity across the Receptor Homodimeric Complex.
Mayo Clinic
2
Spirotetronate polyketides as leads in drug discovery.
University of California San Diego
3
Elimination of a cholecystokinin receptor agonist 'trigger' in an effort to develop positive allosteric modulators without intrinsic agonist activity.
Mayo Clinic
4
Development of a time-resolved fluorescence probe for evaluation of competitive binding to the cholecystokinin 2 receptor.
University of Arizona
5
Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity (II): Optimization of the C3 amino substituent.
Glaxo Wellcome Research and Development
8
Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist"trigger".
Glaxo Wellcome
7
3-[2-(N-phenylacetamide)]-1,5-benzodiazepines: orally active, binding selective CCK-A agonists.
Glaxo Wellcome Research and Development
7
Modification of receptor selectivity and functional activity in cholecystokinin peptoid ligands.
Glaxo Research Institute
12
Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists II: tuning of receptor selectivity and in vivo efficacy.
Johnson & Johnson Pharmaceutical Research and Development
25
Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists I: discovery of CCKR1 selectivity in a previously CCKR2-selective lead series.
Johnson & Johnson Pharmaceutical Research and Development
2
Synthesis and in vitro characterization of radioiodinatable benzodiazepines selective for type 1 and type 2 cholecystokinin receptors.
Mayo Clinic
47
Optimization of 1,3,4-benzotriazepine-based CCK(2) antagonists to obtain potent, orally active inhibitors of gastrin-mediated gastric acid secretion.
James Black Foundation
5
Optimization of the in vitro and in vivo properties of a novel series of 2,4,5-trisubstituted imidazoles as potent cholecystokinin-2 (CCK2) antagonists.
James Black Foundation
11
3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines: CCK-A agonists that demonstrate oral activity as satiety agents.
Glaxo Wellcome Research and Development
9
CCK-A receptor selective antagonists derived from the CCK-A receptor selective tetrapeptide agonist Boc-Trp-Lys(Tac)-Asp-MePhe-NH2 (A-71623).
Glaxo Research Institute
34
Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential.
H. Lundbeck
15
Design and synthesis of trivalent ligands targeting opioid, cholecystokinin, and melanocortin receptors for the treatment of pain.
University of Arizona
17
Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors in Vitro.
Tom'S of Maine
13
Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists.
University of Arizona
95
Designed multiple ligands. An emerging drug discovery paradigm.
Organon Laboratories
18
5-(tryptophylamino)-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based cholecystokinin receptor antagonists: reversal of CCK1 receptor subtype selectivity toward CCK2 receptors.
Instituto De Qu£Mica M£Dica (Csic)
20
Peptide science: exploring the use of chemical principles and interdisciplinary collaboration for understanding life processes.
University of Arizona
20
2002 Alfred Burger Award Address in Medicinal Chemistry. Natural products and design: interrelated approaches in drug discovery.
Merck Research Laboratories
14
5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK(1) receptor antagonists: structure-activity relationship studies on the central 1,3-dioxoperhydropyrido[1,2-c]pyrimidine scaffold.
Instituto De Qu£Mica M£Dica (Csic)
6
5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK(1)receptor antagonists: structure-activity relationship studies on the substituent at N2-position.
Instituto De Qu£Mica M£Dica (Csic)
17
beta-Turned dipeptoids as potent and selective CCK(1) receptor antagonists.
Instituto De Qu£Mica M£Dica (Csic)
8
Development of peptide 3D structure mimetics: rational design of novel peptoid cholecystokinin receptor antagonists.
James Black Foundation
9
CCK peptides with combined features of hexa- and tetrapeptide CCK-A agonists.
AstraZeneca
14
5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK(1) receptor antagonists: structural modifications at the tryptophan domain.
Insituto De Qu�Mica M�Dica (Csic)
32
Second generation"peptoid" CCK-B receptor antagonists: identification and development of N-(adamantyloxycarbonyl)-alpha-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile.
Warner-Lambert
9
Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor.
University of Paris
9
Synthesis and biological evaluation of potent, selective, hexapeptide CCK-A agonist anorectic agents.
Rochester
24
Synthesis and biological properties of new constrained CCK-B antagonists: discrimination of two affinity states of the CCK-B receptor on transfected CHO cells.
University of Paris
6
The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid recepto
University of Arizona
76
Structure-antigastrin activity relationships of new spiroglumide amido acid derivatives.
Rotta Research Laboratorium
10
High-affinity and potent, water-soluble 5-amino-1,4-benzodiazepine CCKB/gastrin receptor antagonists containing a cationic solubilizing group.
Merck Sharp and Dohme Research Laboratories
17
Tetrapeptide CCK-A agonists: effect of backbone N-methylations on in vitro and in vivo CCK activity.
Abbott Laboratories
4
Peptide-linked 1,3-dialkyl-3-acyltriazenes: gastrin receptor directed antineoplastic alkylating agents.
National Cancer Institute-Frederick
24
Tetrapeptide CCK agonists: structure-activity studies on modifications at the N-terminus.
Abbott Laboratories
2
CCK-A-selective tetrapeptides containing lys(N epsilon)-amide residues: favorable in vivo and in vitro effects of N-methylation at the aspartyl residue.
Abbott Laboratories
31
Cholecystokinin dipeptoid antagonists: design, synthesis, and anxiolytic profile of some novel CCK-A and CCK-B selective and"mixed" CCK-A/CCK-B antagonists.
Parke-Davis Neuroscience Research Centre
121
Development of 1,4-benzodiazepine cholecystokinin type B antagonists.
Merck Research Laboratories
21
CCK-B agonist or antagonist activities of structurally hindered and peptidase-resistant Boc-CCK4 derivatives.
University of Paris
25
Amide bond replacements incorporated into CCK-B selective"dipeptoids".
Parke-Davis Neuroscience Research Center
25
Rationally designed"dipeptoid" analogues of CCK. Acid mimics of the potent and selective non-peptide CCK-B receptor antagonist CI-988.
Parke-Davis Neuroscience Research Centre
56
Development of potent and selective CCK-A receptor agonists from Boc-CCK-4: tetrapeptides containing Lys(N epsilon)-amide residues.
Abbott Laboratories
65
Structure-antigastrin activity relationships of new (R)-4-benzamido-5-oxopentanoic acid derivatives.
Rotta Research Laboratorium
23
Rationally designed"dipeptoid" analogues of CCK. alpha-Methyltryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties.
Parke-Davis Research Unit
18
Novel glutamic acid derived cholecystokinin receptor ligands.
Merck Sharp & Dohme Research Laboratories
13
Development of CCK-tetrapeptide analogues as potent and selective CCK-A receptor agonists.
Abbott Laboratories
14
Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260.
Merck Sharp & Dohme Research Laboratories
135
Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists.
Merck Sharp & Dohme Research Laboratories
64
Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists.
TBA
5
Synthesis and biological characterisation of [3H]BBL454, a new CCK2 selective radiolabelled agonist displaying original pharmacological properties.
University of Paris
20
Design of non-peptide CCK2 and NK1 peptidomimetics using 1-(2-nitrophenyl)thiosemicarbazide as a novel common scaffold.
Novartis Institute For Medical Sciences
5
The design and synthesis of the high efficacy, non-peptide CCK1 receptor agonist PD170292.
Ccipe-Faculte De Pharmacie
6
Conversion of acyclic nonpeptide CCK antagonists into CCK agonists
Glaxo Wellcome Research and Development
60
Design and synthesis of a targeted set of aromatic amino acid derivatives for identification of new lead compounds
TBA
16
Identification and biological activity of novel peptidomimetic gastrin/CCK-B receptor agonists
TBA
4
Synthesis of novel iodinated radioligands with high affinity and selectivity for CCK-B/gastrin receptors
TBA
14
The rational design and synthesis of non-peptide rhegnylogues of CCK-26-33 - a novel series of CCK-A selective ligands
TBA
6
Synthesis of a potent and selective non-peptide CCK-B/gastrin receptor antagonist tritiated ligand.
TBA
13
Biological properties of (R)-4-benzamido-5-oxopentanoic basic derivatives as CCK-antagonists
TBA
5
Cholecystokinin analogues: The ergopeptine alkaloids as models of the active conformation of CCK
TBA
9
New anthranilic acid based antagonists with high affinity and selectivity for the human cholecystokinin receptor 1 (hCCK1-R).
University of Trieste
4
A sucrose-derived scaffold for multimerization of bioactive peptides.
The University of Arizona
12
Highly improved metabolic stability and pharmacokinetics of indium-111-DOTA-gastrin conjugates for targeting of the gastrin receptor.
University Medical Centre Ljubljana
32
Discovery of pyrimidine carboxamides as potent and selective CCK1 receptor agonists.
Merck
1
Spiroindolones, a potent compound class for the treatment of malaria.
Swiss Tropical and Public Health Institute
15
Synthesis and pharmacological evaluation of highly potent dual histamine H2 and gastrin receptor antagonists
TBA
29
Design, synthesis, and pharmacological evaluation of dual histamine H2 and gastrin receptor antagonists
TBA
13
C5-piperazinyl-1,4-benzodiazepines, water-soluble, orally bioa vailable CCKB/gastrin receptor antagonists
TBA
8
Potent, selective, water-soluble benzodiazepine-based CCKB receptor antagonists that contain lipophilic carboxylate surrogates
TBA
8
Alternative strategies towards the identification of chemical lead compounds by rational design
TBA
5
α-β-didehydrotryptophan as a surrogate for α-methyltryptophan in CCK ‘peptoids’ related to CI-988.
TBA
12
Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class
TBA
10
Diphenylpyrazolidinone and benzodiazepine cholecystokinin antagonists: A case of convergent evolution in medicinal chemistry
TBA
14
Toward developing peptidomimetics: Successful replacement of backbone amide bonds in tetrapeptide-based CCK-A receptor agonists
TBA
7
Structure-based design and pharmacological properties of potent selective and systemically active CCK-B peptidomimetics
TBA
6
Diastereoselective synthesis of cyclopropyl phenylalanines and their incorporation into dipeptides
TBA
8
Tryptophan-norleucine 1,5-disubstituted tetrazoles as cis peptide bond mimics: Investigation of the bioactive conformation of a potent and selective peptide for the cholecystokinin-B receptor
TBA
5
L-708,474: The C5-cyclohexyl analogue of L-365,260, a selective high affinity ligand for the CCKB/gastrin receptor
TBA
9
1,3,4-trisubstituted pyrrolidinones as scaffolds for construction of peptidomimetic cholecystokinin antagonists
TBA
7
The synthesis and CCK receptor affinities of selected carboyxlic acid mimics of CI-988 - a potent and selective CCK-B antagonist
TBA
8
Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands.
University of Minnesota
46
Discovery of imidazole carboxamides as potent and selective CCK1R agonists.
Merck Research Laboratories
3
Recent natural products based drug development: a pharmaceutical industry perspective.
Bristol Myers Squibb
10
Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors.
University of Arizona
2
Emerging trends of receptor-mediated tumor targeting peptides: A review with perspective from molecular imaging modalities.
Lanzhou University
73
Identification and optimization of anthranilic sulfonamides as novel, selective cholecystokinin-2 receptor antagonists.
Johnson and Johnson Pharmaceutical Research and Development
10
Peptide-based long-acting co-agonists of GLP-1 and cholecystokinin 1 receptors as novel anti-diabesity agents.
Jiangsu Normal University
17
Conformationally constrained CCK4 analogues incorporating IBTM and BTD beta-turn mimetics.
Instituto De QuíMica MéDica (Csic)
5
Combination of molecular modeling, site-directed mutagenesis, and SAR studies to delineate the binding site of pyridopyrimidine antagonists on the human CCK1 receptor.
Instituto De QuíMica MéDica (Csic)
5
Synthesis and medicinal chemistry of tetronamides: Promising agrochemicals and antitumoral compounds.
Universidade Federal De Minas Gerais
38
Amide Bond Bioisosteres: Strategies, Synthesis, and Successes.
University of Nebraska Medical Center
9
Opportunities for Tapping into Three-Dimensional Chemical Space through a Quaternary Carbon.
St. John'S University
6
Stabilization Strategies for Linear Minigastrin Analogues: Further Improvements
Medical University of Innsbruck
5
Effects of the incorporation of IBTM beta-turn mimetics into the dipeptoid CCK(1) receptor agonist PD 170292.
Instituto De QuíMica MéDica (Csic)
48
Pyridine alkaloids with activity in the central nervous system.
University of Auckland
36
Replacement of glycine with dicarbonyl and related moieties in analogues of the C-terminal pentapeptide of cholecystokinin: CCK(2) agonists displaying a novel binding mode.
University of Paris
13
Highly constrained dipeptoid analogues containing a type II' beta-turn mimic as novel and selective CCK-A receptor ligands.
Instituto De QuíMica MéDica (Csic)
56
Structure-Activity Relationships and Characterization of Highly Selective, Long-Acting, Peptide-Based Cholecystokinin 1 Receptor Agonists.
TBA
4
Relationship between dihedral angles of N1 and C9 substituents in 1,4-benzodiazepines and dual cholecystokinin-A and -B antagonistic activities.
Fujisawa Pharmaceutical
17
Novel constrained CCK-B dipeptoid antagonists derived from pipecolic acid.
University of Paris
11
Triazolo-Peptidomimetics: Novel Radiolabeled Minigastrin Analogs for Improved Tumor Targeting.
Eth Zurich
57
Novel nonpeptide CCK-B antagonists: design and development of quinazolinone derivatives as potent, selective, and orally active CCK-B antagonists.
Parke-Davis Pharmaceutical Research
18
Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by (R)-2-(2,4-trifluoromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)- 2, 3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide.
Merck Research Laboratories
12
Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]pyrimidine derivatives: potent and selective cholecystokinin-A receptor antagonists.
Instituto De QuíMica MéDica (Csic)
17
5-(Piperidin-2-yl)- and 5-(homopiperidin-2-yl)-1,4-benzodiazepines: high-affinity, basic ligands for the cholecystokinin-B receptor.
Merck Sharp & Dohme Research Laboratories
15
Minor structural differences in Boc-CCK-4 derivatives dictate affinity and selectivity for CCK-A and CCK-B receptors.
Abbott Laboratories
19
(3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist.
Ferring Research Institute
11
Synthesis, biological evaluation, and quantitative receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as novel tifluadom-like ligands with high affinity and selectivity for kappa-opioid receptors.
Universitá
12
Controlled modification of acidity in cholecystokinin B receptor antagonists: N-(1,4-benzodiazepin-3-yl)-N'-[3-(tetrazol-5-ylamino) phenyl]ureas.
Neuroscience Research Centre
44
Chemistry, binding affinities, and behavioral properties of a new class of"antineophobic" mitochondrial DBI receptor complex (mDRC) ligands.
Mayo Foundation
27
Cholecystokinin peptidomimetics as selective CCK-B antagonists: design, synthesis, and in vitro and in vivo biochemical properties.
University of Paris
13
Development of high-affinity 5-HT3 receptor antagonists. Structure-affinity relationships of novel 1,7-annelated indole derivatives.
Solvay Duphar
8
Second-generation benzodiazepine CCK-B antagonists. Development of subnanomolar analogs with selectivity and water solubility.
Merck Research Laboratories
7
Synthesis and evaluation of cholecystokinin trimers: a multivalent approach to pancreatic cancer detection and treatment.
Pierre and Marie Curie University
19
Ac-[3- and 4-alkylthioproline31]-CCK4 analogs: synthesis and implications for the CCK-B receptor-bound conformation.
Washington University
8
Synthesis and biological evaluation of cholecystokinin analogs in which the Asp-Phe-NH2 moiety has been replaced by a 3-amino-7-phenylheptanoic acid or a 3-amino-6-(phenyloxy)hexanoic acid.
Ep Cnrs 51
18
Discovery of potent cholecystokinin-2 receptor antagonists: elucidation of key pharmacophore elements by X-ray crystallographic and NMR conformational analysis.
Johnson & Johnson Pharmaceutical Research and Development
22
Synthesis and solid-phase purification of anthranilic sulfonamides as CCK-2 ligands.
Johnson & Johnson Pharmaceutical Research and Development
23
Scaffold hopping with molecular field points: identification of a cholecystokinin-2 (CCK2) receptor pharmacophore and its use in the design of a prototypical series of pyrrole- and imidazole-based CCK2 antagonists.
James Black Foundation
58
Synthesis and SAR of new 5-phenyl-3-ureido-1,5-benzodiazepines as cholecystokinin-B receptor antagonists.
Glaxo Wellcome Medicines Research Centre
28
2,7-Dioxo-2,3,4,5,6,7-hexahydro-1H-benzo[h][1,4]diazonine as a new template for the design of CCK(2) receptor antagonists.
James Black Foundation
19
Non-peptide cholecystokinin-B/gastrin receptor antagonists based on bicyclic, heteroaromatic skeletons.
James Black Foundation
32
Improving the affinity and selectivity of a nonpeptide series of cholecystokinin-B/gastrin receptor antagonists based on the dibenzobicyclo[2.2.2]octane skeleton.
James Black Foundation
13
A new class of non-peptidic cholecystokinin-B/gastrin receptor antagonists based on dibenzobicyclo[2.2.2]octane.
James Black Foundation
11
Receptor-Ligand Interaction Measured by Inductively Coupled Plasma Mass Spectrometry and Selenium Labeling.
University of Montpellier
11
Synthesis and biological activity of partially modified retro-inverso pseudopeptide derivatives of the C-terminal tetrapeptide of gastrin.
TBA
14
Cholecystokinin antagonists. Synthesis and biological evaluation of 4-substituted 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepines.
Merck Sharp & Dohme Research Laboratories
18
Synthesis of gastrin antagonists, analogues of the C-terminal tetrapeptide of gastrin, by introduction of a beta-homo residue.
Centre De Pharmacologie-Endocrinologie (Montpellier, France)
14
Synthesis and binding affinities of cyclic and related linear analogues of CCK8 selective for central receptors.
University of Paris
34
Cholecystokinin-A receptor ligands based on the kappa-opioid agonist tifluadom.
Merck Sharp & Dohme Research Laboratories
16
Carboxylic acids and tetrazoles as isosteric replacements for sulfate in cholecystokinin analogues.
Roche Research Center
5
trans-3-n-propyl-L-proline is a highly favorable, conformationally restricted replacement for methionine in the C-terminal tetrapeptide of cholecystokinin. Stereoselective synthesis of 3-allyl- and 3-n-propyl-L-proline derivatives from 4-hydroxy-L-proline.
Abbott Laboratories
50
Cholecystokinin antagonists: (R)-tryptophan-based hybrid antagonists of high affinity and selectivity for CCK-A receptors.
Abbott Laboratories
32
Boc-CCK-4 derivatives containing side-chain ureas as potent and selective CCK-a receptor agonists.
Abbott Laboratories
9
Boc-Trp-Orn(Z)-Asp-NH2 and derivatives: a new family of CCK antagonists.
University of Paris
7
Synthesis and X-ray crystallographic analysis of quinazolinone cholecystokinin/gastrin receptor ligands.
Eli Lilly
19
Synthesis and biological activity of CCK heptapeptide analogues. Effects of conformational constraints and standard modifications on receptor subtype selectivity, functional activity in vitro, and appetite suppression in vivo.
Abbott Laboratories
8
N-methylated analogs of Ac[Nle28,31]CCK(26-33): synthesis, activity, and receptor selectivity.
Hadassah-University Hospital
9
Analogs of CCK incorporating conformationally constrained replacements for Asp32.
Roche Research Center
13
Analogs of Ac-CCK-7 incorporating dipeptide mimics in place of Met28-Gly29.
Roche Research Center
52
Heterocyclic inhibitors of monocarboxylate transporter
The Scripps Research Institute
135
Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors
Ctxt
147
8-(piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline derivatives
Idorsia Pharmaceuticals
61
Substituted amino triazoles useful as human chitinase inhibitors
Oncoarendi Therapeutics
112
Use of pyrazolopyrimidine derivatives for the treatment of PI3K-delta related disorders
Incyte
10
Glycogen phosphorylase inhibitory effects of 2-oxo-1,2-dihydropyridin-3-yl amide derivatives.
Griffith University
17
Design, synthesis, and X-ray crystal structures of 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors.
Duquesne University
14
N-aryl-oxazolidin-2-imine muscle selective androgen receptor modulators enhance potency through pharmacophore reorientation.
Bristol Myers Squibb
47
Discovery of potent inhibitors of interleukin-2 inducible T-cell kinase (ITK) through structure-based drug design.
Boehringer Ingelheim Pharmaceuticals
11
Novel thiol-based TACE inhibitors: rational design, synthesis, and SAR of thiol-containing aryl sulfonamides.
Vertex Pharmaceuticals
25
Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors.
Sunesis Pharmaceuticals
11
Discovery of novel nitrobenzothiazole inhibitors for Mycobacterium tuberculosis ATP phosphoribosyl transferase (HisG) through virtual screening.
Yale University